Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium dihydrogen phosphate + disodium hydrogen phosphate is an enteral electrolyte replacement therapy consisting of a combination of two inorganic phosphate salts. It is being evaluated by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology for the treatment of varying degrees of hypophosphatemia, particularly in critically ill patients. The mechanism of action involves direct supplementation of inorganic phosphorus to restore normal serum phosphorus levels, which is essential for cellular energy metabolism (ATP production), bone mineralization, and maintaining the structural integrity of cell membranes. In the clinical trial context, it is administered as granules via oral or nasogastric routes, with dosing stratified by the severity of the phosphorus deficiency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium dihydrogen phosphate + disodium hydrogen phosphate.